Ignite Creation Date:
2024-05-06 @ 1:50 PM
Last Modification Date:
2024-10-26 @ 1:21 PM
Study NCT ID:
NCT04139317
Status:
TERMINATED
Last Update Posted:
2024-02-08
First Post:
2019-10-14
Brief Title:
Safety and Efficacy of Capmatinib INC280 Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1 50
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis